Skip to main content
logo
Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
6.57
-0.02 (-0.30%)
Aug 26, 2026, 12:58 PM EDT - Market open

Prelude Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
22.4212.147---
Revenue Growth
220.34%73.43%----
Gross Profit
22.4212.147---
Selling, General & Admin
20.2922.3128.7228.8830.6526.96
Research & Development
68.2393.1118103.3992.8986.78
Operating Expenses
88.52115.41146.71132.28123.54113.74
Operating Income
-66.1-103.27-139.71-132.28-123.54-113.74
Other Non Operating Income (Expenses)
6.915.0712.5410.458.12.04
EBT Excluding Unusual Items
-59.19-98.2-127.17-121.83-115.44-111.69
Merger & Restructuring Charges
-1.3-1.3----
Pretax Income
-60.49-99.5-127.17-121.83-115.44-111.69
Net Income
-60.49-99.5-127.17-121.83-115.44-111.69
Net Income to Common
-60.49-99.5-127.17-121.83-115.44-111.69
Net Income Growth
------
Shares Outstanding (Basic)
847776604746
Shares Outstanding (Diluted)
847776604746
Shares Change
10.91%1.52%25.60%27.41%2.87%269.03%
EPS (Basic)
-0.72-1.29-1.68-2.02-2.44-2.43
EPS (Diluted)
-0.72-1.29-1.68-2.02-2.44-2.43
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-33.26-56.37-103.65-110.58-86.75-85.85
Free Cash Flow Per Share
-0.40-0.73-1.37-1.83-1.83-1.86
Gross Margin
100.00%100.00%100.00%---
Operating Margin
-294.76%-850.63%-1995.91%---
Profit Margin
-269.75%-819.59%-1816.76%---
Free Cash Flow Margin
-148.30%-464.32%-1480.74%---
EBITDA
-64.51-101.56-137.94-131.11-122.22-112.82
D&A For EBITDA
1.591.711.771.171.320.92
EBIT
-66.1-103.27-139.71-132.28-123.54-113.74
SEC Filings: 10-K · 10-Q